147 related articles for article (PubMed ID: 11008201)
41. Evaluation of numerical abnormalities of chromosomes 1 and 17 in proliferative epithelial breast lesions using fluorescence in situ hybridization.
Marinho AF; Botelho M; Schmitt FC
Pathol Res Pract; 2000; 196(4):227-33. PubMed ID: 10782466
[TBL] [Abstract][Full Text] [Related]
42. Clonal profiling of mixed lobular and ductal carcinoma revealed by multiplex ligation-dependent probe amplification and fluorescence in situ hybridization.
Tajiri R; Inokuchi M; Sawada-Kitamura S; Kawashima H; Nakamura R; Oyama T; Dobashi Y; Ooi A
Pathol Int; 2014 May; 64(5):231-6. PubMed ID: 24888777
[TBL] [Abstract][Full Text] [Related]
43. Genetic alterations in early-onset invasive breast carcinomas: correlation of c-erbB-2 amplification detected by fluorescence in situ hybridization with p53 accumulation and tumor phenotype.
Fiche M; Avet-Loiseau H; Heymann MF; Moussaly F; Digabel C; Joubert M; Classe JM; Dravet F; Fumoleau P; Ross J; Maugard CM
Int J Cancer; 1999 Oct; 84(5):511-5. PubMed ID: 10502729
[TBL] [Abstract][Full Text] [Related]
44. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry.
Park K; Han S; Kim HJ; Kim J; Shin E
Histopathology; 2006 May; 48(6):702-7. PubMed ID: 16681686
[TBL] [Abstract][Full Text] [Related]
45. [Expression of fatty acid synthase and its association with HER2 in invasive ductal carcinoma of breast].
Yang M; Xu SP; Ao QL
Zhonghua Bing Li Xue Za Zhi; 2013 Apr; 42(4):257-61. PubMed ID: 23928534
[TBL] [Abstract][Full Text] [Related]
46. Extensive apoptosis in ductal carcinoma in situ of the breast.
Bodis S; Siziopikou KP; Schnitt SJ; Harris JR; Fisher DE
Cancer; 1996 May; 77(9):1831-5. PubMed ID: 8646681
[TBL] [Abstract][Full Text] [Related]
47. RET finger protein expression in invasive breast carcinoma: relationship between RFP and ErbB2 expression.
Tezel GG; Uner A; Yildiz I; Guler G; Takahashi M
Pathol Res Pract; 2009; 205(6):403-8. PubMed ID: 19232840
[TBL] [Abstract][Full Text] [Related]
48. Fluorescence in situ hybridization for detecting erbB-2 amplification in breast tumor fine needle aspiration biopsies.
Sauter G; Feichter G; Torhorst J; Moch H; Novotna H; Wagner U; Dürmüller U; Waldman FM
Acta Cytol; 1996; 40(2):164-73. PubMed ID: 8629392
[TBL] [Abstract][Full Text] [Related]
49. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
Ottesen GL
APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
[TBL] [Abstract][Full Text] [Related]
50. Ductal carcinoma in situ of the breast: histological classification and genetic alterations.
van de Vijver MJ
Recent Results Cancer Res; 1998; 152():123-34. PubMed ID: 9928552
[TBL] [Abstract][Full Text] [Related]
51. Correlation of HER2 overexpression with gene amplification and its relation to chromosome 17 aneuploidy: a 5-year experience with invasive ductal and lobular carcinomas.
Nassar A; Khoor A; Radhakrishnan R; Radhakrishnan A; Cohen C
Int J Clin Exp Pathol; 2014; 7(9):6254-61. PubMed ID: 25337277
[TBL] [Abstract][Full Text] [Related]
52. Comparative genomic hybridization of ductal carcinoma in situ of the breast-evidence of multiple genetic pathways.
Buerger H; Otterbach F; Simon R; Poremba C; Diallo R; Decker T; Riethdorf L; Brinkschmidt C; Dockhorn-Dworniczak B; Boecker W
J Pathol; 1999 Mar; 187(4):396-402. PubMed ID: 10398097
[TBL] [Abstract][Full Text] [Related]
53. Possible Prognostic Role of HER2/Neu in Ductal Carcinoma In Situ and Atypical Ductal Proliferative Lesions of the Breast.
Daoud SA; Ismail WM; Abdelhamid MS; Nabil TM; Daoud SA
Asian Pac J Cancer Prev; 2016; 17(8):3733-6. PubMed ID: 27644608
[TBL] [Abstract][Full Text] [Related]
54. Analysis of ERBB2 and TOP2A gene status using fluorescence in situ hybridization versus immunohistochemistry in localized breast cancer.
Bouchalová K; Trojanec R; Kolár Z; Cwiertka K; Cernáková I; Mihál V; Hajdúch M
Neoplasma; 2006; 53(5):393-401. PubMed ID: 17013533
[TBL] [Abstract][Full Text] [Related]
55. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer.
van de Vijver MJ; Peterse JL; Mooi WJ; Wisman P; Lomans J; Dalesio O; Nusse R
N Engl J Med; 1988 Nov; 319(19):1239-45. PubMed ID: 2903446
[TBL] [Abstract][Full Text] [Related]
56. A modified approach for I-FISH evaluation of ERBB2 (HER-2) gene copy numbers in breast carcinomas: comparison with HER-2/CEP17 ratio system.
Mrhalova M; Kodet R
J Cancer Res Clin Oncol; 2007 May; 133(5):321-9. PubMed ID: 17165026
[TBL] [Abstract][Full Text] [Related]
57. Microvessel density, proliferating activity, p53 and bcl-2 expression in in situ ductal carcinoma of the breast.
Zolota V; Gerokosta A; Melachrinou M; Kominea A; Aletra C; Scopa CD
Anticancer Res; 1999; 19(4B):3269-74. PubMed ID: 10652623
[TBL] [Abstract][Full Text] [Related]
58. Association of C-MYC amplification with progression from the in situ to the invasive stage in C-MYC-amplified breast carcinomas.
Robanus-Maandag EC; Bosch CA; Kristel PM; Hart AA; Faneyte IF; Nederlof PM; Peterse JL; van de Vijver MJ
J Pathol; 2003 Sep; 201(1):75-82. PubMed ID: 12950019
[TBL] [Abstract][Full Text] [Related]
59. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast.
Latta EK; Tjan S; Parkes RK; O'Malley FP
Mod Pathol; 2002 Dec; 15(12):1318-25. PubMed ID: 12481013
[TBL] [Abstract][Full Text] [Related]
60. Heterogeneous expression of nm23 gene product in noninvasive breast carcinoma.
Simpson JF; O'Malley F; Dupont WD; Page DL
Cancer; 1994 May; 73(9):2352-8. PubMed ID: 7513249
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
